Ireland's Horizon to buy U.S. drugmaker Hyperion for $1.1 bln
March 30 (Reuters) - Ireland's Horizon Pharma Plc said it would acquire U.S. drugmaker Hyperion Therapeutics Inc in an all-cash deal worth about $1.1 billion.
Horizon will pay $46 per share, representing a premium of 7.6 percent to Hyperion's Friday closing price.
(Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)